Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Moreau, Philippe  [Clear All Filters]
2020
Laurent V, Fronteau C, Antier C, Dupuis P, Tessoulin B, Gastinne T, Mahe B, Blin N, Dubruille V, Lok A, et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2020.
Roussel M, Moreau P, Hébraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol. 2020;7(12):e874-e883.
Di Bacco A, Bahlis NJ, Munshi NC, Avet-Loiseau H, Masszi T, Viterbo L, Pour L, Ganly P, Cavo M, Langer C, et al. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J Haematol. 2020.
Van de Wyngaert Z, Nerich V, Fouquet G, Chrétien M-L, Caillot D, Azar N, Garderet L, Lenain P, Macro M, Bourhis J-H, et al. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transplant. 2020.
Samur MKemal, Samur AAktas, Fulciniti M, Szalat R, Han T, Shammas M, Richardson P, Magrangeas F, Minvielle S, Corre J, et al. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020:JCO2000461.
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert B-M, Daguindau E, Mahe B, Dubruille V, Blin N, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.
Moreau P, Touzeau C, Vij R, Goldsmith SR, Rosko AE. Newly Diagnosed Myeloma in 2020. Am Soc Clin Oncol Educ Book. 2020;40:1-15.